Pershing Edward 4

What Happened
Edward Pershing, CEO and director of Provectus Biopharmaceuticals (PVCT), recorded a derivative conversion on April 4, 2026: the conversion of his 8% unsecured convertible promissory note (the "2025 Note") into 33,977 shares of Series D‑1 Convertible Preferred Stock. The Form 4 reports this as an exercise/conversion of a derivative (transaction code M) showing acquisition of 33,977 derivative shares at $0.00 on the filing. Per the filing footnotes, the conversion price was $2.862 per Series D‑1 preferred share, implying the note converted represented approximately $97,242 of principal/interest. Each Series D‑1 preferred share is convertible into 10 shares of common stock, so these preferred shares are equivalent to up to 339,770 common shares and will automatically convert on December 31, 2028 unless converted earlier.

Key Details

• Transaction date: April 4, 2026 (Form 4 filed April 6, 2026) — appears timely (Form 4 filed within required window).
• Reported on Form 4 as: Exercise/conversion of derivative (code M) — 33,977 shares acquired at $0.00 (derivative).
• Conversion price (per footnote): $2.862 per Series D‑1 preferred share → implied consideration ≈ $97,242.17.
• Common-equivalent: 33,977 Series D‑1 × 10 = 339,770 common shares potentially issuable; automatic conversion date Dec 31, 2028.
• Shares owned after transaction: not specified in the filing.
• Relevant footnotes: conversion of the 2025 Note into Series D‑1 Preferred (footnotes F1–F4).

Context

• This was a conversion of a debt instrument into preferred stock (derivative conversion), not an open‑market buy or sale of common shares. Form 4 lists $0 because the reporting shows the derivative exercise; the underlying note value and conversion price are disclosed in footnotes.
• Preferred shares carry a 10:1 conversion into common stock and will convert automatically at the stated future date unless converted earlier — this could materially increase Pershing’s common share exposure once converted.
• The filing is factual and does not indicate motive; conversions of notes into equity are often part of financing or debt settlement arrangements rather than a direct buy/sell signal.